



# An Expert Opinion on the Role of the Rosuvastatin/Amlodipine Single Pill Fixed Dose Combination in Cardiovascular Prevention

Giovanna Gallo<sup>1</sup> · Riccardo Sarzani<sup>2,3</sup> · Arrigo Francesco Giuseppe Cicero<sup>4,5</sup> · Stefano Genovese<sup>6</sup> · Matteo Pirro<sup>7</sup> · Luca Gallelli<sup>8</sup> · Andrea Faggiano<sup>9</sup> · Massimo Volpe<sup>1,10</sup> 

Received: 21 February 2023 / Accepted: 13 March 2023 / Published online: 5 April 2023  
© The Author(s) 2023

## Abstract

Current cardiovascular disease prevention strategies are based on the management of cardiovascular risk as a continuum, redefining the therapeutic goals for each individual based on the estimated global risk profile. Given the frequent clustering of the principal cardiovascular risk factors, such as hypertension, diabetes and dyslipidaemia, in the same individual, patients are required to take multiple drugs to achieve therapeutic targets. The adoption of single pill fixed dose combinations may contribute to achieve better control of blood pressure and cholesterol compared to the separate administration of the individual drugs, mostly due to better adherence related to therapeutic simplicities. This paper reports the outcomes of an Expert multidisciplinary Roundtable. In particular, the rational and potential clinical use of the single pill fixed dose combination “Rosuvastatin-Amlodipine” for the management of concomitant hypertension/hypercholesterolemia in different clinical fields are discussed. This Expert Opinion also illustrates the importance of an early and effective management of total cardiovascular risk, highlights the substantial benefits of combining blood pressure and lipid-lowering treatments in a single-pill fixed dose combination and attempts to identify and overcome the barriers to the implementation in clinical practice of the fixed dose combinations with dual targets. This Expert Panel identifies and proposes the categories of patients who may benefit the most from this fixed dose combination.

**Keywords** Cardiovascular prevention · Fixed dose combination · Rosuvastatin/Amlodipine · Hypertension · Dyslipidaemia

## 1 Introduction

Cardiovascular diseases (CVD) have an enormous impact on global health, still representing the leading causes of morbidity and mortality worldwide [1].

In such a context, a huge effort has been made in the last decades by National Healthcare Systems, Scientific Societies

as well as by individual physicians in their clinical practice to implement and extend effective preventive strategies with the aim to reduce the burden of CVD.

Current cardiovascular disease prevention strategies are based on the management of cardiovascular risk as a continuum, redefining the therapeutic goals for each individual based on the estimated global risk profile. Given the frequent

✉ Massimo Volpe  
massimo.volpe@uniroma1.it

<sup>1</sup> Department of Clinical and Molecular Medicine, Sapienza University of Rome, Rome, Italy

<sup>2</sup> Internal Medicine and Geriatrics, ‘Hypertension Excellence Centre’ of the European Society of Hypertension, IRCCS INRCA, Ancona, Italy

<sup>3</sup> Department of Clinical and Molecular Sciences, University ‘Politecnica delle Marche’, Ancona, Italy

<sup>4</sup> Hypertension and Cardiovascular Risk Research Unit, Medical and Surgical Sciences Department, Alma Mater Studiorum University of Bologna, Bologna, Italy

<sup>5</sup> IRCCS AOU Policlinico di S. Orsola, Bologna, Italy

<sup>6</sup> Endocrine and Metabolic Diseases Unit IRCCS Centro Cardiologico Monzino, 20138 Milan, Italy

<sup>7</sup> Unit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, Perugia, Italy

<sup>8</sup> Department of Health Sciences, Campus “Salvatore Venuta”, University of Catanzaro “Magna Græcia”, 88100 Catanzaro, Italy

<sup>9</sup> Cardiovascular Unit, Internal Medicine Department, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico di Milano, University of Milan, Milan, Italy

<sup>10</sup> IRCCS San Raffaele Roma, Rome, Italy

clustering of the principal cardiovascular risk factors, such as hypertension, diabetes and dyslipidaemia, in the same individuals, patients are required to take multiple drugs to achieve therapeutic targets. [2]. Moreover, the presence of multiple risk factors (RFs) exponentially increases cardiovascular risk [3]. In a large observational study, the incidence of major cardiovascular events (MACE) was 6-fold greater in hypertensive men with elevated cholesterol concentrations and smoking habit compared to non-smokers subjects with high blood pressure (BP) with normal cholesterol levels [4].

Based on multiple evidence, it appears today quite reasonable to postulate that early preventive management strategies based on control of main RFs may contribute to prevent, or at least delay, the development of organ damage and may reduce the excess of cardiovascular risk [5].

### 1.1 Therapeutic Efficacy of Combinations


Several studies have demonstrated that concomitant treatment of hypertension and dyslipidemia with antihypertensive drugs and statins produce a synergistic and large reduction of cardiovascular risk as compared to the separate management of the same conditions taken separately [6–8]. Figure 1, which is modified from the MRFIT Study, a milestone of cardiovascular prevention history, shows that concomitant slight reductions of BP and cholesterol are expected to produce a reduction of cardiovascular risk quantitatively comparable to those attained with more marked individual reductions of BP or cholesterol [4].

In this regard, it should be also mentioned that statins have been shown to contribute to BP lowering in hypertensive patients, due to their capacity to inhibit vascular smooth muscle cell proliferation, to increase the

bioavailability of nitric oxide, to downregulate type 1 angiotensin II receptors and endothelin-1 production, improving arterial compliance and reducing in large artery stiffness and vascular resistances [9–11]. An alternative interpretation of the BP effect of statin therapy associated with BP drugs was presented [9]. One thousand eight hundred twenty-seven hypertensive patients showed lower 24-h BP ( $-2.8/-7.1$  mmHg), daytime ( $-3.3/-7.6$  mmHg) and night-time BP ( $-2.5/-6.0$  mmHg, all  $P < 0.001$ ). They also showed better ambulatory BP control, even after adjustment for confounding factors. The analyses on the groups derived from the ‘propensity score matching’ (369 patients in each group) confirmed these results (OR = 1.8 for 24-h BP control; OR = 1.6 for daytime BP control; OR = 1.7 for night-time BP control, all  $P < 0.001$ ). The interpretation was that patients that were taking a statin, as shown by the lower cholesterol levels, despite the so called “nocebo” effect, were also more likely to be adherent to antihypertensive therapy [10].

In the SECURE trial, a treatment strategy for secondary prevention with a polypill containing aspirin, ramipril, and atorvastatin in older patients with recent myocardial infarction resulted in a lower risk of major adverse cardiovascular events than an usual-care strategy based on the separate administration of the various medications. The risk reduction observed in the polypill group may be explained at least in part, also in the opinion of the authors, by the increased adherence to treatment [12]. In such a context, adherence to prescribed therapy is defined as the number of refilled prescriptions (on time) over the total duration of the treatment, compliance consists in the number of taken medications (pills) and persistence is the time period during which each individual patients stay on therapy.

**Fig. 1** Relationship between risk factors levels and cardiovascular mortality (Modified from Ref. [4]). Even mild elevations in blood pressure and cholesterol increases the risk of cardiovascular diseases. On the other hand, mild concomitant decreases of both risk factors levels significantly reduce cardiovascular risk, at a level comparable to that achieved with marked decreases of the individual risk factors



### 1.1.1 The Issue of Preserved Therapeutic Adherence

Several studies have demonstrated that adherence to virtuous lifestyle changes and pharmacological prescriptions is a critical component to achieve an adequate control of RFs and to reduce MACE [13]. In a population of hypertensive patients, those who adequately took prescribed BP-lowering agents (adherence > 80%) had a 11%, 10% and 22% lower risk of heart failure (HF), coronary artery disease (CAD) and cerebrovascular disease, respectively, compared to subjects with poor therapeutic adherence [14, 15].

An Italian study stratifying 242,000 patients with newly treated hypertension by the level of adherence (very low < 25%; low 26–50%; intermediate 51–75%; and high > 75%) showed that in the groups with intermediate and high adherence the risk of MACE was 20% and 25% lower, respectively, compared to those with low adherence [16].

In the US cohort of the Veterans Affairs Health System, patients with history of CVD who were poorly adherent to statin treatment had a 30% greater risk of cardiovascular death compared to adherent participants [17].

In a large meta-analysis including two million subjects from 44 studies showed that poor adherence was responsible for 9.1% of all registered MACE, whereas an adequate adherence to statin and BP lowering treatments was able to reduce by 45% and 29%, respectively, the risk of cardiovascular death [18].

The risk of CVD attributable to low adherence is exponentially amplified in people treated for multiple cardiovascular RFs. In a Finnish study including 58,000 patients, those were adherent to both statin and antihypertensive therapies presented a 1.8-fold lower risk of death from stroke compared to subjects non-adherent to statins but adherent to BP-lowering therapy, whereas individuals adherent only to statins had a 1.3-fold increased risk. Moreover, non-adherence to both medications was associated with a 7.4-fold increase in the risk of death from stroke compared with fully adherent patient [19].

A large body of evidence supports the inverse relationship between adherence and the complexity of prescribed regimens. In this view, international guidelines recommend combinations of two or more agents in a fixed dose combination (FDC) as first-line strategies for most patients [20–22].

More recently, the development of FDCs has been advocated also for the treatment of multiple clinical conditions requiring several agents to be used simultaneously in complex regimens.

Several randomized trials have demonstrated that FDCs improve BP and cholesterol control compared to the separate administration of the individual component drugs, with a favorable safety profile and comparable rates of adverse events [23]. These results have been confirmed also in trials (FOCUS, Kanyini-GAP, IMPACT and UMPIRE) conducted

in patients with previous CVD or with an estimated high cardiovascular risk, which have shown that the use of a poly pill improves adherence from 25% to 40% at 12 months [24–27]. A meta-analysis of the Single Pill to Avert Cardiovascular Event (SPACE) Collaboration showed that FDCs significantly reduced systolic BP (– 2.46 mmHg, 95%CI: – 4.55 to – 0.37 mmHg) and low-density lipoprotein cholesterol (LDL-c) (–0.09 mmol/L, 95% CI – 0.18 to 0.00) compared to separate individual agents [28].

In this view, the implementation of the poly pill use has been increasingly suggested as an effective strategy to improve cardiovascular prevention. However, the use of poly pill is less frequent in the context of CVD, due to the relatively low level of global pharmaceutical manufacturing investment, technical challenges and skepticism by clinicians about effectiveness, safety, potential fertility and flexibility. In such a context, it should be underlined that FDCs of different pharmacological classes have been demonstrated to be a safe approach not only as a substitution therapy for patients already receiving medications, but also as a “step-up” therapy in those who were not treated or partially treated [29–32].

In this context, the combination of two widely investigated and long established drugs such as Amlodipine and Rosuvastatin represents an attractive therapeutic solution for implementing cardiovascular preventive therapies.

In this Expert Opinion paper we discuss the potential clinical usefulness of the single pill FDC “Rosuvastatin-Amlodipine” for the management of concomitant hypertension/hypercholesterolemia in different clinical settings was discussed. In the present paper we also provide a synthetic report of the multidisciplinary expert panel opinion regarding the importance of an early and effective management of total CVD risk, highlighting the substantial benefits of combining BP- and lipid-lowering treatments in a single-pill FDC, we also attempted to identify and to overcome the barriers to the persistently poor implementation of the dual target FDC in clinical practice in general and with specific regard to the “Rosuvastatin/Amlodipine” single pill FDC.

## 2 Rosuvastatin: Italian Regulatory Policy and New Perspectives

In Italy regulatory policy identifies Rosuvastatin (both in isolated form and in association with other molecules) as a second-line drug in the therapeutic management of dyslipidemias, allowing reimbursement by the Italian National Healthcare System only after the failure to achieve recommended therapeutic targets or in case of the occurrence of adverse events with a first-line lipid-lowering drug (including Atorvastatin, Pravastatin, Fluvastatin, Lovastatin and Simvastatin). In Italy, on the other hand, the

“legge n.24 2017” also called “Gelli-Bianco” rules about the legal consequences for the physician that not apply current guidelines, guidelines that indicate the use of high-intensity statin from the beginning in many patients with high or very high cardiovascular risk. This is why many physicians do prescribe rosuvastatin as first-line statin even if the low-cost might not be reimbursed.

Indeed, despite the regulatory provision about reimbursement, the analysis of the Italian Market has shown a progressive moderate increase of the prescriptions of Rosuvastatin alone and combined to Ezetimibe in a FDC in the last years. In this context, beside the remarkable efforts made by several pharmaceutical companies to promote the prescription of these combinations, their use is probably less broad than what could be expected. However, a pivotal role is currently played by the significant reduction, both in primary and secondary prevention, of lipid levels targets recommended by international guidelines on the basis of a wide literature [21, 22, 33]. Based on the remarkable scientific literature and authoritative studies performed on Rosuvastatin [34–42] in different clinical settings and published on leading international journals, a much larger number of patients could potentially benefit from the use of this effective and safe lipid-lowering drug to achieve the therapeutic goals currently recommended by all main international guidelines.

Indeed, as shown by several systematic reviews and meta-analyses [39–42], Rosuvastatin is the most effective among high-potency statins (with the exception of Pitavastatin, which however is not widely available) [43] in reducing both total and low density lipoprotein cholesterol (LDL-c). Furthermore, Rosuvastatin is also most effective in increasing high-density lipoprotein cholesterol (HDL-c) levels improving the overall metabolic profile of patients affected by metabolic syndrome. Indeed, the STELLAR (Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin) study showed that rosuvastatin significantly reduced non-HDL-C, apo B, and all lipid and apolipoprotein ratios assessed, compared to milligram-equivalent doses of atorvastatin and milligram-equivalent or to higher doses of simvastatin and pravastatin (all,  $P < 0.002$ ). Rosuvastatin reduced non-HDL-C by 42.0–50.9% compared with 34.4–48.1% with atorvastatin, 26.0–41.8% with simvastatin, and 18.6–27.4% with pravastatin [36, 37].

Beside the class effect of statins to stabilize and slow-down the progression of atherosclerotic plaques, Rosuvastatin has been demonstrated to induce the regression of coronary lesions measured by intravascular ultrasound (IVUS) [44, 45]. Furthermore, in a study conducted with IVUS-virtual histology, Rosuvastatin reduced necrotic core and plaque volume and decreased thin-cap fibroatheroma rate independently from the dose of administration

[46]. Finally, due to its combined lipid-lowering-anti-inflammatory effect [47], Rosuvastatin can reverse the carotid plaque burden in patients suffering from systemic inflammatory diseases such as rheumatoid arthritis [48].

In Italy only 1 out of 9 patients on statins is treated with Rosuvastatin while Atorvastatin is used more frequently partly because Atorvastatin is routinely selected for in-hospital treatment of acute coronary syndrome [49]. On the other hand, an early use of Rosuvastatin in acute settings, even at low-doses, is useful and effective to achieve more rapidly the recommended therapeutic targets, to improve prognosis and to implement adherence also in view of the good tolerability profile [34–42]. Indeed, it seems reasonable to believe that it is more likely to maintain lipid targets over time if they are reached as quickly as possible, with a high potency statins. In fact, international guidelines recommend using high potency statins such as Rosuvastatin and Atorvastatin at the highest tolerable dose to reach therapeutic goals [21].

### 3 The FDC Rosuvastatin-Amlodipine

In the context of hypertension management, the most recent European Guidelines recommend starting treatment with a dual combination of BP-lowering drugs (angiotensin converting enzyme inhibitors /angiotensin receptor blockers plus calcium channel blockers [CCB] or thiazide like diuretics) [20]. In these guidelines, Amlodipine represents One of the first-line effective BP-lowering drugs and, in those patients who present the coexistence of dyslipidemia, the association with statins, in a FDC may appear as a reasonable and feasible solution in clinical practice, also in consideration of the long half-life of this dihydropyridine CCB which provides 24-hour BP lowering effect. In view of a “paradigm shift” towards an approach of a global cardiovascular risk management, this FDC may reduce not only BP and lipid levels, but also contribute to reduce cardiovascular events and mortality, by treating the patients in their complexity [50, 51]. Indeed, the association of Rosuvastatin-Amlodipine, addressing two major cardiovascular RFs simultaneously in a simple and effective way, meets the requirements implied by a more thorough cardiovascular prevention. Moreover, this combination provided in the single-pill formulation appears to be more effective in reducing both BP and lipid values than the two separate agents [51, 52]. Kim and colleagues showed that subjects who received the association Rosuvastatin-Amlodipine achieved the greatest reduction in systolic and diastolic BP levels and in LDL-c levels compared to those who were treated with only Rosuvastatin or Amlodipine. The percentage of patients in which systolic and diastolic BP levels decreased  $\geq 20$  mmHg and  $\geq 10$  mmHg, respectively (about 74%), and in which LDL-c

targets were reached (about 92%) was also highest in the Rosuvastatin-Amlodipine group [51].

#### 4 Potential Implications in Clinical Practice

Different categories of patients may take advantages from the single pill FDC Rosuvastatin-Amlodipine (Summarized in Table 1):

- (1) Subjects at low estimated cardiovascular risk with both high-normal BP (SBP between 130 and 139 mmHg and DBP between 85 and 90 mmHg) or grade 1 hypertension (SBP between 140 and 159 mmHg and DBP between 90 and 99 mmHg), in which a single antihypertensive agent may be sufficient, and moderate dyslipidemia, in which treatment with ezetimibe is not required [53]. In these individuals, the concept that "the earlier, the better" may be appropriate, with great long-term cardiovascular benefits [54].
- (2) Subjects with the "JUPITER" type phenotype, consisting in metabolic syndrome, high-normal BP and elevated high-sensitive C-reactive (hs-CRP) levels. In the JUPITER study [35], indeed, Rosuvastatin (20 mg/day) lowered LDL-c by 55% and hsCRP by 36%, significantly reducing the risk of MACE.
- (3) Subjects with intermediate cardiovascular risk. In the HOPE-3 study conducted in 12,705 participants who did not have CVD and were at intermediate risk
- rosuvastatin 10 mg per day significantly reduced the first coprimary outcome of death from cardiovascular causes, nonfatal MI, or nonfatal stroke, and the second coprimary outcome of revascularization, HF, and resuscitated cardiac arrest [55].
- (4) Patients with multiple comorbidities or treated with complex polytherapies, such as those with HIV on HAART [56], those who receive aromatase inhibitors [56], cancer patients in chemotherapy. In these categories, the use of a safe FDC could at least partially reduce the risk of assumption mistakes and of adverse interactions among the different drugs [56, 57].
- (5) Patients who have experienced an ischemic stroke. Amlodipine plays a very important role in the prevention of ischemic stroke, as demonstrated by the ASCOT study [58]. Moreover, patients with cerebrovascular disease often need to take lipid-lowering therapy and Rosuvastatin has been shown to reduce by about 50% the recurrence of ischemic stroke [59, 60].
- (6) Diabetic patients with high or very-high cardiovascular risk, in which both BP and lipid targets are very stringent according to the most recent Guidelines [61]. To pursue these ambitious objectives, Rosuvastatin, the most powerful high intensity statin with very solid evidence in diabetics, may be proposed as a first therapeutic choice [62]. Moreover, in diabetic patients the combination of the ACEi Benazepril + Amlodipine was superior in terms of cardiovascular endpoints (− 18%, HR 0.82,  $p = 0.02$ ) compared to

**Table 1** Different categories of patients may take advantages from this FDC of "Rosuvastatin-Amlodipine"

Category of patients who may benefit from the FDC "Rosuvastatin-Amlodipine"	Clinical features
Hard-To-Control Hypertensive Patients	Patients who do not achieve BP control with a double antihypertensive therapy in a FDC. A triple antihypertensive therapy in a "dissociated" form may be prescribed: two pills including four active medications
Substitution therapy	Patients who effectively take separately the two drugs especially in complex therapeutic regimens
Patients simultaneously affected by high-normal BP/grade 1 hypertension and moderate dyslipidaemia	Subjects at low estimated CV risk in which a single antihypertensive agent is sufficient to control BP and ezetimibe is not required to manage dyslipidaemia
"JUPITER" Patients	Patients presenting with metabolic syndrome, high-normal BP and elevated high-sensitive C-reactive levels regardless of lipid values
Patients on Polytherapies	Patients with multiple comorbidities on polytherapies (eg elderly, HIV patients on HAART, cancer patients in chemotherapy). The use of a safe FDC could reduce the risk of assumption mistakes and of adverse interactions
Patients who have experienced an ischemic stroke	Both amlodipine and Rosuvastatin play a very important role in the prevention and treatment of ischemic stroke
Diabetic patients	In diabetics both BP and Lipid targets are very stringent. To get these targets, Rosuvastatin is the most powerful high-intensity statin and Amlodipine is one of the antihypertensive agents of choice in diabetics

BP blood pressure, CV cardiovascular, FDC fixed dose combinations, HIV human immunodeficiency virus, HAART highly active antiretroviral therapy

the association of Benazepril + hydrochlorothiazide, with a lower risk of worsening of renal function [63]. Another important issue to consider is that increasing adherence and therapeutic compliance is essential to cope with chronic diseases such as diabetes. A retrospective cohort study conducted on 11,532 diabetic patients showed that those who adhered to the prescribed therapy had better BP, glucose and lipid control and a reduced risk of all-cause mortality (4.0% vs 5.9%,  $p < 0.001$ ) and hospitalizations (19.2% vs 23.2%,  $p < 0.001$ ) [64]. Another study showed that the costs related to hospitalization of diabetics are significantly higher in non-adherent patients [65]. Therefore, ensuring adequate therapeutic compliance is also sustainable in pharmaco-economic terms. In such a context, a strategy that has proved extremely effective in improving therapeutic adherence is exactly the prescription of FDCs such as Rosuvastatin-Amlodipine [24, 30, 31].

- (7) Patients already taking separately Rosuvastatin and Amlodipine with good results within a complex therapeutic scheme (substitution therapy)
- (8) Patients who do not achieve BP control with a double antihypertensive therapy in a FDC. A triple antihypertensive therapy in a “dissociated” form can represent a solution. The combination of Rosuvastatin-Amlodipine could allow to manage concomitant RFs with just two pills including four active medications. For instance, through single-pill FDC with a renin angiotensin-system blocker plus a thiazide-like diuretic. The combinations of different FDC offers many advantages and is a novel way to reduce cardiovascular risk by enhancing adherence and persistence in drug therapy.

## 5 Conclusion

In conclusion, although not yet broadly adopted in the clinical practice, the single-pill FDC “Rosuvastatin-Amlodipine” represents a rational combination of two effective, evidence-based, safe and well tolerated drugs to approach the treatment of two major RFs like hypertension and hypercholesterolemia, hence reducing cardiovascular events and their related burden. This multidisciplinary Expert Panel composed by physicians with competence in the different areas prevention of cardiovascular disease believes that this FDC could prove to be an extremely useful approach in different clinical settings (e.g. diabetics, patients who have experienced an ischemic stroke, etc..) both for increasing drug adherence in complex patients suffering from multiple

diseases and for reducing the global burden of cardiovascular disease.

**Acknowledgements** The Authors wish to thank Zentiva Italia for the support given to the finalization of the Expert Panel Roundtable

**Funding** Open access funding provided by Università degli Studi di Roma La Sapienza within the CRUI-CARE Agreement.

**Data availability** Not applicable.

## Declarations

**Funding** None to disclose.

**Conflict of interest** The authors report the following conflict of interest. AFGC: Speaker for Sharper SpA, Piam SpA and SPA SpA., consulting in AB from Zentiva. MV: Speaker or participation to AB. Menarini International, Novo Nordisk, Zentiva. RS, SG, LG, MP: consulting in AB from Zentiva GG and AF: personal fees as medical writers from Zentiva.

**Ethical standards** The manuscript was written in accordance with the ethical standard.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.

## References

1. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018;392(10159):1736–88. [https://doi.org/10.1016/S0140-6736\(18\)32203-7](https://doi.org/10.1016/S0140-6736(18)32203-7).
2. Asia Pacific Cohort Studies Collaboration. Joint effects of systolic blood pressure and serum cholesterol on cardiovascular disease in the Asia Pacific region. *Circulation*. 2005;112(22):3384–90.
3. Volpe M, Erhardt LR, Williams B. Managing cardiovascular risk: the need for change. *J Hum Hypertens*. 2008;22(2):154–7.
4. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple risk factor intervention trial research group. *Arch Intern Med*. 1992;152:56–64.
5. Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management? *Int J Cardiol*. 2018;254:328–32.
6. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen

- J, Nieminen M, O'Brien E, Ostergren J, ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet*. 2003;361(9364):1149–58. [https://doi.org/10.1016/S0140-6736\(03\)12948-0](https://doi.org/10.1016/S0140-6736(03)12948-0).
7. Multiple risk factor intervention trial. Risk factor changes and mortality results. Multiple Risk Factor Intervention Trial Research Group. *JAMA*. 1982;248(12):1465-77
  8. Schwalm JD, McKee M, Huffman MD, Yusuf S. Resource effective strategies to prevent and treat cardiovascular disease. *Circulation*. 2016;133(8):742–55.
  9. Spannella F, Filippini A, Giuliotti F, Di Pentima C, Bordoni V, Sarzani R. Statin therapy is associated with better ambulatory blood pressure control: a propensity score analysis. *J Hypertens*. 2020;38(3):546–55210.
  10. Tocci G, Presta V, Citoni B, Figliuzzi I, Coluccia R, Battistoni A, Musumeci MB, De Biase L, Ferrucci A, Volpe M. Favourable impact of statin use on diastolic blood pressure levels: analysis of a large database of 24-hour ambulatory blood pressure monitoring. *J Hypertens*. 2017;35(10):2086–94. <https://doi.org/10.1097/HJH.0000000000001419>.
  11. Borghi C, Fogacci F, Agnoletti D, Cicero AFG. Hypertension and dyslipidemia combined therapeutic approaches. *High Blood Press Cardiovasc Prev*. 2022;29(3):221–30. <https://doi.org/10.1007/s40292-022-00507-8>.
  12. Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda JC, Barczy G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, Proietti M, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibañez B, Fuster V, SECURE Investigators. Polypill strategy in secondary cardiovascular prevention. *N Engl J Med*. 2022;387(11):967–77.
  13. Pedretti RFE, Hansen D, Ambrosetti M, Back M, Berger T, Ferreira MC, Cornelissen V, Davos CH, Doehner W, de Pablo Y, Zarzosa C, Frederix I, Greco A, Kurpas D, Michal M, Osto E, Pedersen SS, Salvador RE, Simonenko M, Steca P, Thompson DR, Wilhelm M, Abreu A. How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases: a clinical consensus statement from the European Association of Preventive Cardiology. *Eur J Prev Cardiol*. 2023;30(2):149–66.
  14. Perreault S, Dragomir A, Roy L, White M, Blais L, Lalonde L, Bérard A. Adherence level of antihypertensive agents in coronary artery disease. *Br J Clin Pharmacol*. 2010;69(1):74–84. <https://doi.org/10.1111/j.1365-2125.2009.03547.x>.
  15. Kettani FZ, Dragomir A, Côté R, Roy L, Bérard A, Blais L, Lalonde L, Moreau P, Perreault S. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. *Stroke*. 2009;40(1):213–20. <https://doi.org/10.1161/STROKEAHA.108.522193>.
  16. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. *J Hypertens*. 2011;29(3):610–8. <https://doi.org/10.1097/HJH.0b013e328342ca97>.
  17. Rodriguez F, Maron DJ, Knowles JW, Virani SS, Lin S, Heidenreich PA. Association of statin adherence with mortality in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol*. 2019;4:206–13.
  18. Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, Stricker B, Mendis S, Hofman A, Mant J, Franco OH. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. *Eur Heart J*. 2013;34(38):2940–8. <https://doi.org/10.1093/eurheartj/ehd295>.
  19. Herttua K, Martikainen P, Batty GD, Kivimaki M. Poor adherence to statin and antihypertensive therapies as risk factors for fatal stroke. *J Am Coll Cardiol*. 2016;67:1507–15.
  20. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021–104.
  21. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O, ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41(1):111–88.
  22. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumhach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J*. 2021;42(36):3599–3726
  23. de Cates AN, Farr MR, Wright N, Jarvis MC, Rees K, Ebrahim S, Huffman MD. Fixed-dose combination therapy for the prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2014;4(4):CD009868.
  24. Castellano JM, Sanz G, Peñalvo JL, Bansilal S, Fernández-Ortiz A, Alvarez L, Guzmán L, Linares JC, García F, D'Aniello F, Arnáiz JA, Varea S, Martínez F, Lorenzatti A, Imaz I, Sánchez-Gómez LM, Roncaglioni MC, Baviera M, Smith SC Jr, Taubert K, Pocock S, Brotons C, Farkouh ME, Fuster V. A polypill strategy to improve adherence: results from the FOCUS project. *J Am Coll Cardiol*. 2014;64(20):2071–82. <https://doi.org/10.1016/j.jacc.2014.08.021>.
  25. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, Neal B, Hillis GS, Rafter N, Tonkin A, Webster R, Billot L, Bompont S, Burch C, Burke H, Hayman N, Molanus B, Reid CM, Shiel L, Togni S, Rodgers A, Kanyini Guidelines Adherence with the Polypill (Kanyini GAP) Collaboration. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. *Eur J Prev Cardiol*. 2015;22(7):920–30. <https://doi.org/10.1177/2047487314530382>.
  26. Selak V, Elley CR, Bullen C, Crengle S, Wadham A, Rafter N, Parag V, Harwood M, Doughty RN, Arroll B, Milne RJ, Bramley D, Bryant L, Jackson R, Rodgers A. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. *BMJ*. 2014;348:g3318. <https://doi.org/10.1136/bmj.g3318>.
  27. Thom S, Poulter N, Field J, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Bompont S, Billot L, Rodgers A, UMPIRE Collaborative Group. Effects of a fixed-dose combination strategy on adherence and risk factors in

- patients with or at high risk of CVD: the UMPIRE randomized clinical trial. *JAMA*. 2013;310(9):918–29. <https://doi.org/10.1001/jama.2013.277064>.
28. Webster R, Patel A, Selak V, Billot L, Bots ML, Brown A, Bullen C, Cass A, Crengle S, Raina Elley C, Grobbee DE, Neal B, Peiris D, Poulter N, Prabhakaran D, Rafter N, Stanton A, Stepien S, Thom S, Usherwood T, Wadham A, Rodgers A, SPACE Collaboration. Effectiveness of fixed dose combination medication ('polypills') compared with usual care in patients with cardiovascular disease or at high risk: A prospective, individual patient data meta-analysis of 3140 patients in six countries. *Int J Cardiol*. 2016;205:147–56. <https://doi.org/10.1016/j.ijcard.2015.12.015>.
  29. Webster R, Murphy A, Bygrave H, Ansbro É, Grobbee DE, Perel P. Implementing fixed dose combination medications for the prevention and control of cardiovascular diseases. *Glob Heart*. 2020;15(1):57K.T.
  30. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*. 2007;120(8):713–9. <https://doi.org/10.1016/j.amjmed.2006.08.033>.
  31. Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. *J Gen Intern Med*. 2008;23(5):611–4. <https://doi.org/10.1007/s11606-008-0544-x>.
  32. Huffman MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. *Lancet*. 2017;389(10073):1055–65. [https://doi.org/10.1016/S0140-6736\(17\)30553-6](https://doi.org/10.1016/S0140-6736(17)30553-6).
  33. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol*. 2019;74(10):e177–232. <https://doi.org/10.1016/j.jacc.2019.03.010>.
  34. Perez-Calahorra S, Laclaustra M, Marco-Benedi V, Pinto X, Sanchez-Hernandez RM, Plana N, Ortega E, Fuentes F, Civeira F. Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence. *Lipids Health Dis*. 2019;18(1):216. <https://doi.org/10.1186/s12944-019-1153-x>.
  35. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ, JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med*. 2008;359(21):2195–207. <https://doi.org/10.1056/NEJMoa0807646>.
  36. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW, STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR\* Trial). *Am J Cardiol*. 2003;92(2):152–60. [https://doi.org/10.1016/s0002-9149\(03\)00530-7](https://doi.org/10.1016/s0002-9149(03)00530-7).
  37. Hirsch M, O'Donnell JC, Jones P. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. *Eur J Cardiovasc Prev Rehabil*. 2005;12(1):18–28.
  38. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. *Eur Heart J*. 2005;26(24):2664–72. <https://doi.org/10.1093/eurheartj/ehi482>.
  39. Yebo HG, Aschmann HE, Kaufmann M, Puhon MA. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. *Am Heart J*. 2019;210:18–28. <https://doi.org/10.1016/j.ahj.2018.12.007>.
  40. Adams SP, Sekhon SS, Wright JM. Lipid-lowering efficacy of rosuvastatin. *Cochrane Database Syst Rev*. 2014. <https://doi.org/10.1002/14651858.CD010254.pub2>.
  41. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. *Eur J Prev Cardiol*. 2016;23(7):744–7. <https://doi.org/10.1177/2047487315598710>.
  42. Zhang L, Zhang S, Yu Y, Jiang H, Ge J. Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol: a meta-analysis of trials with East Asian populations. *Herz*. 2020;45(6):594–602. <https://doi.org/10.1007/s00059-018-4767-2>.
  43. Adams SP, Alaeiikhchi N, Wright JM. Pitavastatin for lowering lipids. *Cochrane Database Syst Rev*. 2020;6(6):CD012735. <https://doi.org/10.1002/14651858.CD012735.pub2>.
  44. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. *JAMA*. 2006;295(13):1556–65. <https://doi.org/10.1001/jama.295.13.jpc60002>.
  45. Puri R, Libby P, Nissen SE, Wolski K, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Tuzcu EM, Nicholls SJ. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN. *Eur Heart J Cardiovasc Imaging*. 2014;15(4):380–8. <https://doi.org/10.1093/ehjci/jet251>.
  46. Banach M, Serban C, Sahebkar A, Mikhailidis DP, Ursoniu S, Ray KK, Rysz J, Toth PP, Muntner P, Mosteoru S, García-García HM, Hovingh GK, Kastelein JJ, Serruys PW, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. *BMC Med*. 2015;13:229. <https://doi.org/10.1186/s12916-015-0459-4>.
  47. Qasim S, Alamgeer M, Kalsoom S, Shahzad M, Bukhari IA, Vohra F, Afzal S. Rosuvastatin attenuates rheumatoid arthritis-associated manifestations via modulation of the pro- and anti-inflammatory cytokine network: a combination of in vitro and in vivo studies. *ACS Omega*. 2021;6(3):2074–84.
  48. Rollefstad S, Ikdahl E, Hisdal J, Olsen IC, Holme I, Hammer HB, Smerud KT, Kitas GD, Pedersen TR, Kvien TK, Semb AG. Rosuvastatin-induced carotid plaque regression in patients with inflammatory joint diseases: the rosuvastatin in rheumatoid arthritis, ankylosing spondylitis and other inflammatory joint diseases Study. *Arthritis Rheumatol*. 2015;67(7):1718–28. <https://doi.org/10.1002/art.39114>.
  49. Wang WT, Hellkamp A, Doll JA, Thomas L, Navar AM, Fonarow GC, Julien HM, Peterson ED, Wang TY. Lipid testing and statin dosing after acute myocardial infarction. *J Am Heart Assoc*. 2018;7(3): e006460.
  50. Chapman RH, Yeaw J, Roberts CS. Association between adherence to calcium-channel blocker and statin medications and likelihood of cardiovascular events among US managed care enrollees. *BMC Cardiovasc Disord*. 2010;10:29. <https://doi.org/10.1186/1471-2261-10-29>.
  51. Kim W, Chang K, Cho EJ, Ahn JC, Yu CW, Cho KI, Kim YJ, Kang DH, Kim SY, Lee SH, Kim U, Kim SJ, Ahn YK, Lee CH, Shin JH, Kim M, Park CG. A randomized, double-blind clinical



- trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension. *J Clin Hypertens*. 2020;22(2):261–9. <https://doi.org/10.1111/jch.13774>. (Epub 2020 Jan 31).
52. Sarzani R, Laureti G, Gezzi A, Spannella F, Giulietti F. Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient. *Ther Adv Chronic Dis*. 2022;24(13):20406223221102750.
  53. Spannella F, Giulietti F, Di Pentima C, Sarzani R. Prevalence and control of dyslipidemia in patients referred for high blood pressure: the disregarded “Double-Trouble” lipid profile in overweight/obese. *Adv Ther*. 2019;36(6):1426–37. <https://doi.org/10.1007/s12325-019-00941-6>.
  54. Tobert JA, Preiss D. Now is good, earlier is better. *Eur Heart J Qual Care Clin Outcomes*. 2017;3(4):256–7. <https://doi.org/10.1093/ehjqcco/qcx027>.
  55. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusuf K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E, HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. *N Engl J Med*. 2016;374(21):2021–31.
  56. Kostapanos MS, Milionis HJ, Elisaf MS. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. *Am J Cardiovasc Drugs*. 2010;10(1):11–28. <https://doi.org/10.2165/13168600-000000000-00000>.
  57. Osterloh IH. An update on the safety of amlodipine. *J Cardiovasc Pharmacol*. 1991;17(Suppl 1):S65–8. <https://doi.org/10.1097/00005344-199117001-00020>.
  58. Gupta A, Mackay J, Whitehouse A, Godec T, Collier T, Pocock S, Poulter N, Sever P. Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial. *Lancet*. 2018;392(10153):1127–37. [https://doi.org/10.1016/S0140-6736\(18\)31776-8](https://doi.org/10.1016/S0140-6736(18)31776-8).
  59. Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez D, Rico-Corral MA. Statins in ischemic stroke prevention: what have we learned in the post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) decade? *Curr Treat Options Neurol*. 2019;21(5):22. <https://doi.org/10.1007/s11940-019-0563-4>.
  60. Heo JH, Song D, Nam HS, Kim EY, Kim YD, Lee KY, Lee KJ, Yoo J, Kim YN, Lee BC, Yoon BW, Kim JS, EUREKA Investigators. Effect and safety of rosuvastatin in acute ischemic stroke. *J Stroke*. 2016;18(1):87–95. <https://doi.org/10.5853/jos.2015.01578>.
  61. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Jüni P, Lettino M, Marx N, Mellbin LG, Östgren CJ, Rocca B, Roffi M, Sattar N, Seferović PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255–323. <https://doi.org/10.1093/eurheartj/ehz486>.
  62. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt B, ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. *J Am Coll Cardiol*. 2010;56(1):77–85. <https://doi.org/10.1016/j.jacc.2010.02.046>.
  63. Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. *Lancet*. 2010;375(9721):1173–81.
  64. García-Pérez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in patients with type 2 diabetes. *Diabetes Ther*. 2013;4(2):175–94. <https://doi.org/10.1007/s13300-013-0034-y>.
  65. Kennedy-Martin T, Boye KS, Peng X. Cost of medication adherence and persistence in type 2 diabetes mellitus: a literature review. *Patient Prefer Adherence*. 2017;11:1103–17. <https://doi.org/10.2147/PPA.S136639>.